CoChat

Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease

McFarlane, Samy I., Sowers, James R. · 2003 · The Journal of Clinical Endocrinology & Metabolism
Cited by 67

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes and its complications are increasing rapidly in Westernized, industrialized societies, in part, because the population is aging and becoming more obese and sedentary (1–6). Type 2 diabetes is also more common in minority populations, including Hispanics and African Americans, whose relative numbers are increasing in this country (1). Up to 20 million people in the United States have diabetes, of whom approximately 4–5 million are unaware that they have this disorder (5, 6). Diabetes is the most frequent underlying cause of new blindness, end stage renal disease, and lower extremity amputations in the United States (1–3). Diabetes also leads to premature cardiovascular disease (CVD; Refs. 2–4), stroke (7–13), and markedly increased premature mortality (2, 3). The role of the renin-angiotensin aldosterone system (RAAS) in increasing the risk for hypertension and CVD in patients with type 2 diabetes has recently engendered considerable interest (13–22). In this review, we will present the evidence supporting the role of aldosterone as a risk factor above and beyond that of angiotensin II (Ang II) in the pathophysiology of CVD in people with diabetes. We will also discuss the potential benefits of blocking the cardiovascular and renal actions of aldosterone in lessening the burden of CVD and renal disease in these patients (13–25). CVD, including stroke and congestive heart failure, accounts for up to 80% of excess deaths in people with type 2 diabetes (2, 3, 7–13). The risk of coronary artery disease is increased 2- to 4-fold in those with diabetes compared with those without diabetes, and the risk of stroke is two to three times higher in persons with diabetes (2, 4, 7–13). In women, diabetes is a particularly important factor for the development of coronary artery disease, stroke, and congestive heart failure (14). The major risk factors for CVD in patients with type 2 diabetes are hypertension, dyslipidemia, smoking, etc. (2–4, 7–12), but the presence of type 2 diabetes markedly accentuates these conventional risk factors (7–12). Hypertension, especially systolic hypertension, occurs much more frequently in persons with diabetes and is a major risk factor for CVD, end stage renal disease, and stroke in these patients (2–4, 8, 15–17). Hypertension, hyperglycemia, cigarette and alcohol use are modifiable risk factors for stroke (18–20). In 8 yr of observation in the United Kingdom Prospective Diabetes Study (UKPDS), increased risk of stroke was strongly associated with systolic hypertension as well as atrial fibrillation (10–21). Accumulating evidence indicates that diabetic renal disease (glomerulosclerosis) and vascular disease (atherosclerosis) run parallel courses in persons with type 2 diabetes (15, 17). There is also increasing data indicating that albuminuria is a predictor of CVD and stroke as well as progression of diabetic renal disease (5, 8, 15, 17). Albuminuria usually clusters with other components of the cardiometabolic syndrome (Ref. 17 ; Table 1). Factors that cluster in the cardiometabolic syndrome Modified from Ref. 17 . HDL, High-density lipoprotein; LDL, low-density lipoprotein. Factors that cluster in the cardiometabolic syndrome Modified from Ref. 17 . HDL, High-density lipoprotein; LDL, low-density lipoprotein. Considerable evidence suggests that components of the RAS exert similar pathological effects on the renal glomerulus as in the systemic and cerebral vasculature (21, 25–28). Thus, interruption of the system would be anticipated to produce parallel improvement in renal and CVD outcome (13, 15). Heart failure is growing in this country because of our aging population, because more persons are surviving their myocardial infarctions, and because of the increasing prevalence of diabetes, particularly in our elderly population (2, 3, 7, 12). There is also accumulating evidence that RAS activation is an important contributor to development of heart failure (Refs. 21 and 26 ; Fig. 1), and this will be explored further in this review. Data from several recent intervention trials also suggest that treatment strategies that reduce the RAS can impact stroke incidence, severity, and recurrence in patients with type 2 diabetes mellitus. For example, in the UKPDS trial for combined fatal and nonfatal stroke, tight blood pressure control [with either an angiotensin converting enzyme (ACE) inhibitor or β-blocker] to a mean level 144/82 mm Hg resulted in a striking 44% relative risk reduction compared with less aggressive control, a mean level of 154/87 mm Hg (10, 12). In the Micro-HOPE subanalysis of the Heart Outcomes Prevention Evaluation (HOPE) study, 35% of diabetic patients treated with the ACE inhibitor, ramipril, had a stroke reduction of 37% (22). Recent studies have shown the benefits of angiotensin receptor blockers (ARBs; Ref. 23) and an ACE/diuretic combination (24) in reduction of primary and secondary strokes in high-risk patients, including patients with diabetes (

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2002-021443

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 67

Metadata

Authors
McFarlane, S. I., & Sowers, J. R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2003-02-01
Volume
88
Issue
2
Pages
516-523
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2077108818
Cited by
67
References
12
FWCI
3.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease. https://app.cochat.ai/papers/10.1210/jc.2002-021443
The paper
McFarlane, S. I., & Sowers, J. R. (2003). Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2002-021443

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.